
CLAIMS

1. A pharmaceutical composition, comprising the following components in weight portions:

(a) 1 weight part of the compound of formula (I)



(I); and

(b) 15 to 45 weight parts of copovidone with a glass transition temperature of 90 ^{o}C to 130 ^{o}C,

wherein components (a) and (b) are mixed and undergo hot melt extrusion.

2. The pharmaceutical composition of claim 1, wherein components (a) and (b) are mixed and undergo hot melt extrusion at a temperature in the range of 80 ^{o}C -135 ^{o}C.

3. The pharmaceutical composition of claim 1, comprising 20 to 40 weight parts of copovidone.

4. The pharmaceutical composition of claim 1, comprising 22 to 33 weight parts of copovidone.

5. The pharmaceutical composition of claim 1, further comprising:

(c) 0.1 to 3.0 weight parts of one or more pharmaceutically acceptable excipients selected from the group consisting of non-volatile weak acids, neutral or weakly acidic inorganic substances, and pharmaceutically acceptable excipients with melting point lower than 80 ^{o}C, wherein components (a), (b) and (c) are mixed and undergo hot melt extrusion at a temperature in the range of 80 ^{o}C -135 ^{o}C.

6. The pharmaceutical composition of claim 5, wherein the one or more pharmaceutically acceptable excipients comprise anhydrous citric acid, citric acid monohydrate, or a mixture

thereof.

7. The pharmaceutical composition of claim 5, wherein the one or more pharmaceutically acceptable excipients comprise one or more excipients selected from the group consisting of mannitol, lactose monohydrate, lactose anhydrous, sorbitol, calcium hydrogen phosphate anhydrous and colloidal silicon dioxide.

8. The pharmaceutical composition of claim 5, wherein the one or more pharmaceutically acceptable excipients comprise one or more excipients selected from the group consisting of polyethylene glycol, such as polyethylene glycol 4000, polyethylene glycol 6000; lipidic materials; antioxidants, such as 2,6-di-tert-butyl-p-cresol, vitamin E; surfactants, such as Poloxamer 188, Tween 80.

9. The pharmaceutical composition of claim 5, wherein the one or more pharmaceutically acceptable excipients comprise one or more excipients selected from the group consisting of triethyl citrate and polyethylene glycol succinate.

10. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated in a tablet or capsule form.

11. A method for preparing the pharmaceutical composition of any one of claims 1 to 10, comprising the steps of:

extruding a mixture of components (a) and (b) by hot melt extrusion at hot melt extrusion temperature between 80 ^{o}C and 135 ^{o}C to form an extrusion product;

cooling the extrusion product; and

breaking the cooled extrusion product into granules, particles or powders by cutting, crushing or grinding.

12. The method of claim 11, further comprising the step of:

processing the granules, particles or powders obtained in the breaking step into tablets, capsules.

13. The method of claim 11, wherein the mixture of components (a) and (b) is extruded with a twin screw hot melt extrusion device; wherein the screw diameter of the twin screw hot

melt extrusion device is between 8 mm and 50 mm, and the extrusion speed is between 10 rpm and 300 rpm, wherein retention time of the hot melt extrusion is less than 30 min.

14. A pharmaceutical composition of any one of claims 1 to 10, for use in the treatment of steatohepatitis.